<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2627">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334265</url>
  </required_header>
  <id_info>
    <org_study_id>2020 research 110</org_study_id>
    <nct_id>NCT04334265</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019</brief_title>
  <official_title>Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of Anluohuaxian in blocking the progression of pulmonary
      fibrosis and improving lung function in patients with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinical institutions that enroll patients with corona virus disease 2019, two arms,
      multi-center, randomized and controlled methods are adopted. Patients are divided into two
      groups, Anluohuaxian combined with regular treatment group and regular treatment group. 750
      patients are expected to be enrolled and the cases are allocated according to the ratio of 2(
      Anluohuaxian combined with regular treatment group): 1(regular treatment group).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in high-resolution computer tomography of the lung</measure>
    <time_frame>3 months</time_frame>
    <description>Changes in ground-glass shadows, interstitial or air nodules found on high-resolution computer tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6-minute walking distance</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in compound physiological index</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the scores of the St. George's Hospital Respiratory Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>St. George's Hospital Respiratory Questionnaire range from 0 to 100. 0 stands for no impact on life and 100 stands for extreme impact on life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores</measure>
    <time_frame>3 months</time_frame>
    <description>mMRC score range from 0 to 4. 0 stands for wheezing only when exercising hard and 4 stands for severe breathing difficulties.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in vital capacity of the lung</measure>
    <time_frame>3 months</time_frame>
    <description>Adult male vital capacity is about 3,500 ml and female is about 2,500 ml.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Anluohuaxian combined with regular treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anluohuaxian: 6g each time, twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>regular treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anluohuaxian</intervention_name>
    <description>6g each time, twice a day</description>
    <arm_group_label>Anluohuaxian combined with regular treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed COVID-19, and the nucleic acid test of respiratory specimens such as sputum
             or nasopharyngeal swabs is negative twice after the treatment (sampling interval is at
             least 24 hours);

          2. Negative nucleic acid test of respiratory specimens such as sputum or nasopharyngeal
             swabs during screening visits;

          3. High-resolution CT of the lung (HRCT) indicates pulmonary fibrosis (thickness of
             lobular septum, honeycomb-like changes, with or without bronchial / pleural
             distraction);

          4. Voluntarily participate in research and sign informed consent.

        Exclusion Criteria:

          1. Combined with severe heart, lung (diagnosed with interstitial lung disease, bronchial
             asthma, chronic obstructive pulmonary disease, etc.), liver and kidney disease or with
             endocrine, rheumatic, neurologic, malignant and other systemic diseases;

          2. Have been diagnosed with connective tissue disease;

          3. Pregnant or lactating women;

          4. History of mental disorders, substance abuse or dependence;

          5. Have used other anti-pulmonary fibrosis drugs in the past 14 days, such as nidanib,
             pirfenidone, penicillamine, colchicine, tumor necrosis factor alpha blocker, imatinib,
             glucocorticoid hormones, morphomycodyl esters, azathioprine, cyclophosphamide,
             interferon-Î³, and traditional Chinese medicine;

          6. Researchers consider it inappropriate to participate in research;

          7. Participating in other clinical research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guiqiang Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guiqiang Wang</last_name>
    <phone>13911405123</phone>
    <email>john131212@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Zhao</last_name>
    <phone>13810765943</phone>
    <email>zhaohong_pufh@bjmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second People's Hospital of Fuyang</name>
      <address>
        <city>Fuyang</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianfeng Han</last_name>
      <phone>13955881280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ezhou Central Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junhua Yu</last_name>
      <phone>13908688619</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huoshenshan Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sibin Zhang</last_name>
      <phone>13911992121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinyintan Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingyu Zhang</last_name>
      <phone>13507117929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qin Ning</last_name>
      <phone>13971521450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Hospital Union Hospital Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xi Zheng</last_name>
      <phone>18602724981</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuhan Pulmonary Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianxiang Chen</last_name>
      <phone>18971570937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenshun Cheng</last_name>
      <phone>13627288300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenzhou Medical University Affiliated First Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongping Chen</last_name>
      <phone>13505777281</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Guiqiang Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anluohuaxian</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

